Key result
High platelet to lymphocyte ratio (>137) in patients with acute myocardial infarction undergoing primary PCI was associated with more no-reflow (p<0.001) and higher in-hospital mortality (p=0.008).
Why the study?
Does a high platelet to lymphocyte ratio predict adverse outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention?
Population
440 patients with acute myocardial infarction who underwent primary percutaneous coronary intervention
Comparison
High platelet to lymphocyte ratio (PLR > 137) vs Low platelet to lymphocyte ratio (PLR < 137)
Design
Cohort
Follow-up
in-hospital
Authors
Loading...
PLR should not yet guide risk stratification in AMI; leaves open its prognostic value pending prospective validation.
Observational (n=440)
Does a high platelet to lymphocyte ratio predict adverse outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention?
p-value: p=<0.001 for no-reflow, 0.008 for mortality
A high platelet to lymphocyte ratio is an independent predictor of no-reflow, higher Syntax scores, and in-hospital adverse events in patients with AMI undergoing primary PCI.
Ayça et al. (2014) conducted an observational in acute myocardial infarction (n=440). High platelet to lymphocyte ratio (>137) vs. Low platelet to lymphocyte ratio (<137) was evaluated on no-reflow, Syntax scores, and in-hospital mortality rate (p=<0.001 for no-reflow, 0.008 for mortality). High platelet to lymphocyte ratio (>137) in patients with acute myocardial infarction undergoing primary PCI was associated with more no-reflow (p<0.001) and higher in-hospital mortality (p=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: